» Articles » PMID: 36291816

Changes of Protein Expression After CRISPR/Cas9 Knockout of MiRNA-142 in Cell Lines Derived from Diffuse Large B-Cell Lymphoma

Abstract

Background: As microRNA-142 (miR-142) is the only human microRNA gene where mutations have consistently been found in about 20% of all cases of diffuse large B-cell lymphoma (DLBCL), we wanted to determine the impact of miR-142 inactivation on protein expression of DLBCL cell lines.

Methods: miR-142 was deleted by CRISPR/Cas9 knockout in cell lines from DLBCL.

Results: By proteome analyses, miR-142 knockout resulted in a consistent up-regulation of 52 but also down-regulation of 41 proteins in GC-DLBCL lines BJAB and SUDHL4. Various mitochondrial ribosomal proteins were up-regulated in line with their pro-tumorigenic properties, while proteins necessary for MHC-I presentation were down-regulated in accordance with the finding that miR-142 knockout mice have a defective immune response. CFL2, CLIC4, STAU1, and TWF1 are known targets of miR-142, and we could additionally confirm AKT1S1, CCNB1, LIMA1, and TFRC as new targets of miR-142-3p or -5p.

Conclusions: Seed-sequence mutants of miR-142 confirmed potential targets and novel targets of miRNAs can be identified in miRNA knockout cell lines. Due to the complex contribution of miRNAs within cellular regulatory networks, in particular when miRNAs highly present in RISC complexes are replaced by other miRNAs, primary effects on gene expression may be covered by secondary layers of regulation.

Citing Articles

Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer.

Lara P, Aguilar-Gonzalez A, Martin F, Mesas C, Moreno J, Rama A Genes (Basel). 2025; 16(2).

PMID: 40004462 PMC: 11855122. DOI: 10.3390/genes16020133.


Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.

Hu W, Zang L, Feng X, Zhuang S, Chang L, Liu Y Ann Hematol. 2024; 103(12):5085-5101.

PMID: 39652169 DOI: 10.1007/s00277-024-06131-x.


Profiling of microRNAs by next-generation sequencing: Potential biomarkers for diffuse large B-cell lymphoma.

Bahashwan S, Alsaadi M, Barefah A, Almahdi H, Alahwal H, Almohammadi A J Taibah Univ Med Sci. 2024; 19(3):619-627.

PMID: 38812724 PMC: 11133910. DOI: 10.1016/j.jtumed.2024.04.010.


Therapeutic Potential of CRISPR/Cas in Hashimoto's Thyroiditis: A Comprehensive Review.

Upreti A, Mukherjee S Curr Gene Ther. 2024; 24(3):179-192.

PMID: 38310457 DOI: 10.2174/0115665232266508231210154930.


The miRNA-target interactions: An underestimated intricacy.

Diener C, Keller A, Meese E Nucleic Acids Res. 2023; 52(4):1544-1557.

PMID: 38033323 PMC: 10899768. DOI: 10.1093/nar/gkad1142.


References
1.
Tanaka K, Takeda S, Mitsuoka K, Oda T, Kimura-Sakiyama C, Maeda Y . Structural basis for cofilin binding and actin filament disassembly. Nat Commun. 2018; 9(1):1860. PMC: 5945598. DOI: 10.1038/s41467-018-04290-w. View

2.
Zhou C, Zhang Y, Yan R, Huang L, Mellor A, Yang Y . Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. Cell Death Differ. 2020; 28(2):715-729. PMC: 7862304. DOI: 10.1038/s41418-020-00618-6. View

3.
Alles J, Menegatti J, Motsch N, Hart M, Eichner N, Reinhardt R . miRNA expression profiling of Epstein-Barr virus-associated NKTL cell lines by Illumina deep sequencing. FEBS Open Bio. 2016; 6(4):251-63. PMC: 4821355. DOI: 10.1002/2211-5463.12027. View

4.
Mildner A, Chapnik E, Varol D, Aychek T, Lampl N, Rivkin N . MicroRNA-142 controls thymocyte proliferation. Eur J Immunol. 2017; 47(7):1142-1152. DOI: 10.1002/eji.201746987. View

5.
Yang L, Wang Z, Wu H, Wang W . miR-142-5p Improves Neural Differentiation and Proliferation of Adipose-Derived Stem Cells. Cell Physiol Biochem. 2018; 50(6):2097-2107. DOI: 10.1159/000495054. View